Oct72020 Combination Study with JS016 and LY-CoV555 for Patients with Mild-to-Moderate COVID-19 Symptoms Met Primary and Secondary Endpoints Press Release
Sep282020 JUPITER-02 Phase III Global Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival in Recurrent or Metastatic Nasopharyngeal Carcinoma Press Release
Sep102020 Junshi Biosciences Receives FDA Breakthrough Therapy Designation for Toripalimab Press Release
Jul132020 Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement Press Release
Jul122020 Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 Press Release
May262020 Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies Press Release
May42020 Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19 Press Release
Mar302020 Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab Press Release
